Frankfurt - Delayed Quote EUR

Xenon Pharmaceuticals Inc. (XP0.F)

26.20
-0.20
(-0.76%)
As of 8:02:54 AM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
7,500
0
0
9,434
18,437
Cost of Revenue
0
--
--
--
--
Gross Profit
3,500
--
--
--
--
Operating Expense
300,495
279,298
214,054
138,577
97,430
Operating Income
-292,995
-279,298
-214,054
-129,143
-78,993
Net Non Operating Interest Income Expense
38,671
41,943
27,620
8,713
466
Other Income Expense
-1,196
-1,064
3,749
-4,825
-361
Pretax Income
-255,520
-238,419
-182,685
-125,255
-78,888
Tax Provision
-4,074
-4,089
-292
118
-6
Net Income Common Stockholders
-251,446
-234,330
-182,393
-124,936
-77,087
Diluted NI Available to Com Stockholders
-251,446
-234,330
-182,393
-124,936
-77,087
Basic EPS
-3.22
--
-2.73
-2.06
-1.77
Diluted EPS
-3.22
--
-2.73
-2.06
-1.77
Basic Average Shares
78,167.87
--
66,889.01
60,542.14
43,627.45
Diluted Average Shares
78,167.87
--
66,889.01
60,542.14
43,627.45
Total Operating Income as Reported
-292,995
-279,298
-214,054
-129,143
-78,993
Total Expenses
300,495
279,298
214,054
138,577
97,430
Net Income from Continuing & Discontinued Operation
-251,446
-234,330
-182,393
-125,373
-78,882
Normalized Income
-250,269.07
-233,284.09
-186,134.50
-121,812.63
-78,521.03
Interest Income
38,671
41,943
27,620
8,713
466
Interest Expense
--
--
--
0
0
Net Interest Income
38,671
41,943
27,620
8,713
466
EBIT
-292,995
-279,298
-214,054
-129,143
-78,993
EBITDA
-290,362
-276,738
-211,993
-127,738
-78,087
Reconciled Depreciation
2,633
2,560
2,061
1,405
906
Net Income from Continuing Operation Net Minority Interest
-251,446
-234,330
-182,393
-125,373
-78,882
Total Unusual Items Excluding Goodwill
-1,196
-1,064
3,749
-4,825
-361
Total Unusual Items
-1,196
-1,064
3,749
-4,825
-361
Normalized EBITDA
-289,166
-275,674
-215,742
-122,913
-77,726
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-19.07
-18.09
7.50
-1,264.63
-0.03
12/31/2021 - 12/4/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4DN.F Denali Therapeutics Inc.
12.54
+1.42%
 
WXXWY WuXi Biologics (Cayman) Inc.
6.08
+2.13%
 
ADAG Adagene Inc.
1.7700
+1.14%
 
VIGL Vigil Neuroscience, Inc.
2.3200
-2.11%
 
BLTE Belite Bio, Inc
67.07
+8.88%
 
BCDA BioCardia, Inc.
2.3200
-16.85%
 
2269.HK WuXi Biologics (Cayman) Inc.
23.550
-1.26%
 
KYMR Kymera Therapeutics, Inc.
30.02
+0.91%
 
RCUS Arcus Biosciences, Inc.
8.57
+0.35%
 
CLSD Clearside Biomedical, Inc.
0.8645
+1.23%